Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Discovery of mechanism by which Zika virus enters brain cells

Two independent studies published by Cell Press on January 16, 2020, report that the mechanism by which Zika virus enters brain cells has been identified and even more, exploited to prevent Zika infection and to kill cancer cells instead.

16 Jan 2020

Researchers identify new mechanism associated with p53 mutation

More than half of cancer cases worldwide are associated with genetic mutations in p53, the protein responsible for protecting DNA from changes that can lead to cancer.

9 Jan 2020

Researchers discover glioblastoma origins using brain organoids

Glioblastomas are the most aggressive form of brain cancer -; they grow and spread rapidly through the brain and are virtually impossible to eradicate, typically leading to death within one or two years of diagnosis.

6 Jan 2020

Mount Sinai awarded more than $10 million in federal funding for research on glioblastoma

The Department of Neurosurgery at the Icahn School of Medicine at Mount Sinai has received more than $10 million in federal funding for several projects focusing on brain tumor research.

2 Jan 2020

Lab-grown brain organoids may hold the answers to personalized treatments for glioblastomas

Lab-grown brain organoids developed from a patient's own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it.

26 Dec 2019

Immunosupressant combination therapy for glioblastoma shows promise

Researchers from the University of Texas have found an immunosuppressing target for the treatment of glioblastoma. In mice studies the team has identified CD73 macrophages which could be used to treat the cancers. The team also performed studies on human tumours to arrive at their conclusions. The study was published in the latest issue of the journal Nature Medicine this week.

23 Dec 2019

NFCR-funded translational cancer research project receives $700,000 from Virginia Catalyst

A translational research project supported by the National Foundation for Cancer Research (NFCR) has been awarded $700,000 from Virginia Catalyst to advance its lead cancer drug candidate.

23 Dec 2019

Discovery of novel mechanism by which certain breast cancers can metastasize

Researchers from the Baylor College of Medicine and Harvard Medical School have found a novel mechanism to explain the resistance of certain breast cancers that spread in the major organs of the body. They hope that this would help develop new therapeutic strategies to treat the cancer.

12 Dec 2019

Scientists use novel technology for opening blood-brain barrier with implantable ultrasound

One of most potent drugs for treatment of glioblastoma, the most deadly type of brain tumor, can't be used in patients because of two problems. First, it can't reach its target because it's blocked by the blood-brain barrier, a microscopic structure that protects the brain from toxins in the blood. And the conventional formulation for this drug is toxic to the brain.

12 Dec 2019

Important biomarker may help in determining prognosis of brain cancer patients

A common virus that is harmless to most individuals may produce an important biomarker in determining the prognosis of brain cancer patients, according to a recent study published by a student researcher at the University of Cincinnati.

9 Dec 2019

UPV researchers develop new methodology to monitor patients with glioblastoma

Glioblastoma is the most aggressive brain tumor in adults. Now, it can be treated with neurosurgery, radiotherapy and chemotherapy. Still, the median life expectancy of patients affected with this pathology is no longer than 15 months.

5 Dec 2019

Newer safer way to effectively treat deadly brain cancer

A new engineering solution may help deliver tumor killing drugs directly to the brain tumor without the toxic body effects of systemic chemotherapy. The new study published in the journal Nature Scientific Reports reports on the use of coaxial electrospinning, an industrial fabrication technology, in the production of membranes that incorporate drugs to treat glioblastoma multiforme (GBM), an aggressive cancer of the brain.

3 Dec 2019

Researchers develop new strategy for treating the most aggressive type of brain cancer

Researchers from the University of São Paulo in Brazil have developed a strategy for treating the most aggressive type of brain cancer in adults that combines a photoactive molecule and a chemotherapeutic agent - both encapsulated in protein-lipid nanoparticles.

27 Nov 2019

Extra DNA scooped up alongside cancer-causing genes helps drive tumor growth

One of the ways a cancer-causing gene works up enough power to turn a normal cell into a cancer cell is by copying itself over and over, like a Xerox machine.

21 Nov 2019

Fosun Pharma, MimiVax to jointly develop and commercialize SurVaxM therapy in U.S.

The inventors of a new and unique cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, known as SurVaxM. MimiVax LLC principals Robert Fenstermaker, MD, and Michael Ciesielski, PhD, have announced that the company, spun off from Roswell Park in 2012, has entered into a China-exclusive licensing agreement for SurVaxM with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical Co. Ltd. based in Shanghai, China.

20 Nov 2019

Cell factors decide if a cancer grows or dies, says new study

A new study published today in the journal Cell Reports by scientists at the German Cancer Research Center (DKFZ) shows that the direction taken by a cancer cell depends on the configuration of the cell itself as well as the activation of a universal cancer cell receptor called CD95.

19 Nov 2019

Study on sea sponge opens up possibilities to create new antitumor drugs

Chemists from Far Eastern Federal University's School of Natural Sciences developed a new method to synthesize biologically active derivatives of fascaplysin -- cytotoxic pigment of a sea sponge. For the first time, they got a sufficient amount of 3-bromofascaplysin and 3,10-dibromofascaplysin, which were known before but were not available for study.

14 Nov 2019

Researchers identify potential drug targets for glioblastoma

Researchers at Karolinska Institutet in Sweden have identified 10 tumor-specific potential drug targets for the brain tumor glioblastoma. The results are presented in the scientific journal Cell Reports.

5 Nov 2019

Liquid biopsy can predict prognosis in patients with glioblastoma

A blood test that measures the amount of cell-free DNA (cfDNA) in the bloodstream - called a liquid biopsy - correlates with how patients will progress after they are diagnosed with glioblastoma (GBM), the deadliest and most common primary brain tumor in adults.

30 Oct 2019

NYU researcher awarded $1.7 million NIH grant to optimize cancer treatment

Weiqiang Chen, assistant professor of biomedical engineering and mechanical and aerospace engineering at the NYU Tandon School of Engineering, has been awarded the Maximizing Investigators' Research Award (R35) from the National Institute of General Medical Sciences, a division of the National Institutes of Health.

29 Oct 2019